Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Revenue of Erasca, Inc. (ERAS)
Revenue in 2023 (TTM): $
According to Erasca, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Erasca, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-3,732,000 | $-121,310,000 | $-125,042,000 | $-125,042,000 |
| 2022 | $ | $-2,641,000 | $-240,164,000 | $-242,805,000 | $-238,160,000 |
| 2021 | $ | $-829,000 | $-121,935,000 | $-122,764,000 | $-150,090,000 |
| 2020 | $ | $-540,000 | $-101,120,000 | $-101,660,000 | $-173,069,000 |
| 2019 | $ | $-310,000 | $-12,984,000 | $-12,040,000 | $-10,737,000 |